文献速递基础与转化研究新药、器械与细胞基因治疗研发

增强过继性T细胞疗法以克服实体瘤诱导的免疫抑制

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression.
PubMed 文献 · Sci Transl Med · 2019-01-01

过继性T细胞疗法(含CAR T细胞)在部分B细胞恶性肿瘤中获FDA批准,但实体瘤应答率仍不理想。本综述讨论靶向检查点通路、调节代谢通路及构建产细胞因子T细胞等调控免疫抑制肿瘤微环境的策略,这些策略在临床前模型和患者中均显著增强了过继性T细胞免疫治疗的效果。

要点

  • CAR T细胞在部分B细胞恶性肿瘤中成功并获FDA批准,但实体瘤应答率仍较低。
  • 靶向检查点通路、调节代谢通路和产细胞因子T细胞可增强过继性T细胞疗效。
  • 上述增强策略已在临床前模型和患者中显示效果。

核心结论

  • 靶向检查点通路、调节代谢通路及构建产细胞因子T细胞等调控免疫抑制肿瘤微环境的策略,已在临床前模型和患者中显著增强过继性T细胞免疫治疗对实体瘤的疗效。

研究设计与样本

  • 综述,讨论增强CAR T细胞在实体瘤中抗肿瘤应答的最新策略。

主要发现

  • CAR T细胞在部分B细胞恶性肿瘤中取得巨大成功,促使FDA批准该疗法用于某些类型白血病和淋巴瘤。
  • 针对实体瘤的应答率迄今仍较低。
  • 靶向检查点通路、调节代谢通路和构建产细胞因子T细胞等策略在临床前模型和患者中显著增强了过继性T细胞免疫治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of new cancer immunotherapies including checkpoint blockade and chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment. CAR T cells have shown tremendous success in certain B cell malignancies, resulting in U.S. Food and Drug Administration (FDA) approval of this approach for certain types of leukemia and lymphoma. However, response rates against solid cancer have been less successful to date. Approaches to modulate the immunosuppressive tumor microenvironment including targeting checkpoint pathways, modulating metabolic pathways, and generating cytokine-producing T cells have led to considerable enhancement of adoptive T cell immunotherapy, first in preclinical models and now in patients. This review provides a discussion of the most recent strategies to enhance the efficacy of CAR T cell antitumor responses in solid cancers.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Mardiana S, Solomon BJ, Darcy PK, et al. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci Transl Med. 2019. PMID: 31167925. doi:10.1126/scitranslmed.aaw2293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。